Form 4: Keros Therapeutics Director Jean Jacques Bienaime Acquires 17,600 Stock Options
SEC Form 4 Filing
Director Jean Jacques Bienaime of Keros Therapeutics, Inc. acquired 17,600 stock options on June 3, 2024, at a price of $48.67.
Summary
- On June 3, 2024, Jean Jacques Bienaime, a director of Keros Therapeutics, Inc., acquired 17,600 stock options.
- The exercise price of these options is $48.67.
- The options vest in equal quarterly installments commencing on September 3, 2024, with one-twelfth of the shares vesting each quarter, contingent upon continued service.
- The expiration date for these options is June 2, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Future Outlook
The stock options vest quarterly starting September 3, 2024, contingent on the reporting person's continued service.
Industry Context
This Form 4 filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of transaction: Jean Jacques Bienaime acquired 17,600 stock options. |
| 09/03/2024 | Vesting start date: One-twelfth of the shares subject to the option shall vest in equal quarterly installments commencing on this date. |
| 06/02/2034 | Expiration date of the stock options. |
| 06/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.